Amgen updates IMDELLTRA label via BLA supplement; registers romosozumab bioavailability trialSep 11Weekly roundup, 2 itemsAmgenromosozumab-aqqg
Amgen registers Phase 3 trial comparing subcutaneous and IV tarlatamab in relapsed ES-SCLCAug 21Trial updateAmgentarlatamab-dlle
Zai Lab reports Q2 2026 results, advances zoci and ZL-1503 toward key milestonesAug 6Quarterly updateZai Lab (Shanghai) Co., Ltd.ZL-1503
Royalty Pharma raises 2026 guidance after 14% Royalty Receipts growth in Q2Aug 5Quarterly updateRoyalty Pharma plc
Sign inSign in